NCT05225428 Video Education With Result Dependent dIsclosure
| NCT ID | NCT05225428 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Genetic Testing |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,020 participants |
| Start Date | 2022-08-04 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,020 participants in total. It began in 2022-08-04 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma * Ability to understand spoken or written English or Spanish in a healthcare context * Ability to understand and the willingness to sign a written informed consent document * Black or Latinx (qualitative assessment study only) Exclusion Criteria: * Prior cancer genetic testing * Prior germline genetic testing * Active hematologic malignancy (e.g. chronic lymphocytic leukemia) * Currently pregnant * Currently incarcerated
Contact & Investigator
Huma Q. Rana, MD., MPH
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT05225428 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Genetic Testing. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05225428 currently recruiting?
Yes, NCT05225428 is actively recruiting participants. Contact the research team at humaQ_rana@dfci.harvard.edu for enrollment information.
Where is the NCT05225428 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05225428 clinical trial?
NCT05225428 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Huma Q. Rana, MD., MPH at Dana-Farber Cancer Institute. The trial plans to enroll 1,020 participants.